Monitor for continued insider selling patterns and upcoming earnings or clinical trial updates; no immediate red flag, but sustained selling could signal muted confidence if not explained by 10b5-1 plans.
CRBU drugs
CRBU drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Feb 24 $2.14entry
- T+1 · 9mo ago −8.88%α −9.71% · $1.95
- T+5 · 9mo ago −17.76%α −16.73% · $1.76
- T+20 · 8mo ago −14.95%α −9.97% · $1.82
- T+60 · 6mo ago −7.94%α −14.69% · $1.97
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Multiple C-suite executives at Caribou Biosciences (CRBU) sold shares in a coordinated cluster over a 7-day window, totaling approximately $35,500 in sales. On the same dates, these insiders also received substantial stock awards (totaling hundreds of thousands of shares), indicating the sales were part of pre-arranged 10b5-1 plans or compensation-related exercises. The activity aligns with recent insider selling trends and appears routine rather than reactive to material non-public information.
Key Financial Metrics
Key Facts
- Four C-suite executives sold shares on February 24, 2026, at $1.96 per share, totaling $35,454.44 in aggregate.
- On February 20, 2026, the same executives received stock awards ranging from 45,000 to 55,000 shares, valued at zero because they are newly granted.
- The sales are likely part of pre-scheduled 10b5-1 plans or option exercises tied to compensation, not discretionary market timing.
- Total value of insider sales in the last 30 days is $35K, consistent with this cluster.
- No open-market buying activity observed in the cluster.
Financial Impact
$35,454 in insider sales; offset by $0 cost basis in awards received
Risk Factors
- Perception of insider pessimism if sales are not clearly tied to pre-arranged plans.
- Potential dilution from large stock awards if not offset by performance-based vesting.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CONTEXT: Insider Cluster Data (8 trades, 7d window) | cluster-CRBU-1771984517304 |
Track record
13 reports on CRBU
3 of 3 bullish or bearish reports moved the stock their way by T+20. Best: +28.02% at T+20 after the Oct 6, 2026 report. 4 of 4 went positive at some point.
Filters
- Nov 5, 202611d ago 8-K Bearish 7/10 Entry $0.4487 Now $0.3530 +21.33% settles Dec 7
- Oct 6, 20265w ago 8-K Bearish 7/10 Entry $0.6174 to $0.4444 Now $0.3530 +42.82% ▲ +28.02% +26.68% vs SPY
- Sep 22, 20267w ago Institutional Cluster Mixed 3/10 Entry $1.34 to $0.5190 Now $0.3530 −73.66% ▼ −61.27% −60.71% vs SPY
- Jun 11, 202622w ago 8-K Bullish 6/10 Entry $1.66 to $1.94 Now $0.3530 −78.73% ▲ +16.87% +14.98% vs SPY
- Jun 11, 202622w ago Press Release Bullish 7/10 Entry $1.66 to $1.94 Now $0.3530 −78.73% ▲ +16.87% +14.98% vs SPY
- Jun 5, 202623w ago DEFA14A Neutral 2/10 Entry $1.84 to $1.83 Now $0.3530 −80.82% ▼ −0.54% −2.17% vs SPY
- Apr 24, 202629w ago DEFA14A Neutral 3/10 Entry $2.13 to $2.16 Now $0.3530 −83.43% ▲ +1.41% −3.55% vs SPY
- Mar 5, 202636w ago 8-K Mixed 5/10 Entry $1.82 to $1.95 Now $0.3530 −80.60% ▲ +7.14% +9.19% vs SPY
- Mar 5, 202636w ago Press Release Mixed 6/10 Entry $1.82 to $1.95 Now $0.3530 −80.60% ▲ +7.14% +9.19% vs SPY
- Feb 28, 202637w ago Institutional Cluster Neutral 5/10 Entry $1.84 to $1.72 Now $0.3530 −80.82% ▼ −6.52% +1.42% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers